BEOVU Versus Eylea in the Treatment of Age-related Macular Neovascular Degeneration

Outcome of Brolucizumab-dbll and Aflibercept Intravitreal Injection in the Treatment of Age-related Macular Neovascular Degeneration

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04882956

Enrollment

Registered

2021-05-12

Start date

2020-08-05

Completion date

2022-03-31

Last updated

2021-05-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Macula Lutea Degeneration

Keywords

macular degeneration, BEOVU, Eylea

Brief summary

Age-Related macular neovascularization degeneration occur is a vision threatening condition. The investigators compare the efficacy of BEOVU and Eylea intravitreal treatment in the management.

Detailed description

Baseline ,and postoperative 1 ,6 and 12 months full ophthalmic examination was done. Procedure included randomized intravitreal injection of Brolucizumab (BEOVU®, Genentech, South Francisco, CA) and of aflibercept (Eylea; Regeneron, Tarrytown,NY)

Interventions

DRUGintravitreal injection

Brolucizumab-Dbll intravitreal injection

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* • Age-Related macular neovascularization degeneration

Exclusion criteria

* other causes of macular neovascularization degeneration * other macular diseases

Design outcomes

Primary

Measure	Time frame	Description
Best corrected visual acuity (BCVA)	12 months	Change in BCVA in LOG MARS(logarithm minimum angle of resolution

Countries

United Arab Emirates

Contacts

Primary ContactTarek R Elhamaky, MD

thamaky@ibnnafees.com+97126324200

Backup ContactTarek Elhamaky, MD

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026